

Arpit Rao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5136811/publications.pdf>

Version: 2024-02-01

20
papers

335
citations

1307594

7
h-index

888059

17
g-index

20
all docs

20
docs citations

20
times ranked

334
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 946-958.	10.7	100
2	NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. <i>Cancers</i> , 2020, 12, 2659.	3.7	54
3	Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 309-320.	3.8	42
4	Survival outcomes for advanced kidney cancer patients in the era of targeted therapies. <i>Annals of Translational Medicine</i> , 2018, 6, 165-165.	1.7	38
5	Telehealth in cancer care during COVID-19: disparities by age, race/ethnicity, and residential status. <i>Journal of Cancer Survivorship</i> , 2022, 16, 44-51.	2.9	36
6	Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer—Where Are We Now?. <i>Cancers</i> , 2022, 14, 801.	3.7	23
7	A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1531-1539.	7.0	9
8	Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2598-2611.	4.1	8
9	Telehealth: Reducing or increasing cancer care disparities?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1582-1582.	1.6	5
10	Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility?. <i>Annals of Translational Medicine</i> , 2019, 7, S354-S354.	1.7	4
11	Characterization of microsatellite instability (dMMR/MSI-H) and mutational landscape in a large contemporary cohort of upper tract urothelial cancer (UTUC) patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 465-465.	1.6	4
12	Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer. <i>ESMO Open</i> , 2020, 5, e000943.	4.5	2
13	Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in , and on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2020, 8, 106-115.	0.4	2
14	Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS194-TPS194.	1.6	2
15	Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 287-287.	1.6	2
16	Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5063-5063.	1.6	1
17	Falsely Undetectable Prostate-Specific Antigen (PSA) Due to Presence of an Inhibitory Serum Factor: A Case Report and Review of Pertinent Literature. <i>American Journal of Case Reports</i> , 2019, 20, 1248-1252.	0.8	1
18	The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-9.	2.4	1

#	ARTICLE	IF	CITATIONS
19	Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, TPS5107-TPS5107.	1.6	1
20	A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5043-5043.	1.6	0